Hematology and Oncology Book

http://www.fpnotebook.com/

Ximelagatran

Advertisement

  1. Background
    1. No longer available (off market in U.S.)
    2. Listed for historical reasons only
  2. Indications: Non-Valvular Atrial Fibrillation
    1. Warfarin intolerant
    2. Patients with high risk of Intracranial Hemorrhage
  3. Advantages
    1. As effective as Warfarin with INR 2-3
    2. Ximelagartan does not require monitoring
    3. Ximelagartan has fewer bleeding complications
  4. Disadvantages
    1. Expensive
    2. Myocardial Ischemia risk
    3. Risk of severe liver toxicity
  5. Dosing
    1. Studies used fixed dose of 36 mg bid
  6. References
    1. Albers (2005) JAMA 293:690
    2. Olsson (2003) Lancet 362:1691

ximelagatran (C0966370)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHC426686
Englishxi-melagatran, ximelagatran, Ximelagratan
Spanishximelagratan
Parent ConceptsDirect thrombin inhibitor (C1532225)
SourcesMSH, SCTSPA, SNOMEDCT, VANDF
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree